Table 1 Identification of TCRs for the most relevant MAGE-C2/CT10-specific T-cell clones

From: Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients

TCC no.

TRBV

TRBJ

TRBD

CDR3 beta

TRAV

TRAJ

CDR3 alpha

MAGE-C2 peptide specificity

3

7-3*01

2-3*01

2*02

CASSLTGSAPTDTQYF

8-1*01

37*01

CAVKVNNAGNMLTF

311–330

10

6-1*01

2-4*01

1*01

CASSEHGQGVPAKNIQYF

8-1*01

43*01

CAVNARNNNDMRF

171–190

20

7-8*01

1-6*01

1*01

CASSLDLDRGNSPLHF

2*01

29*01

CAVEAYSGNTPLVF

171–190

24

2*01

2-7*01

1*01

CASSLGGQLREQYF

26-1*01

47*01

CIVRGLREYGNKLVF

291–310

33

5-1*01

1-2*01

1*01

CASSLALKAEDGYTF

3*01

9*01

CAVRDPHTGGFKTIF

241–260

35

7-7*01

2-7*01

2*01

CASSQNKVGEQYF

12-2*02

8*01

CAVNEDFQKLVF

261–280

  1. Abbreviations: CDR3, complementarity determining region 3; TCC, T-cell clone; TRAV/TRBV, T-cell receptor alpha/beta chain.
  2. TCR alpha and beta chain compositions according to the IMGT nomenclature are given.